Post-Doctoral Research Associate

PhD (1999): The University of Hong Kong, PR China
Master of Medicine (1990): Beijing Medical University, PR China
Bachelor of Medicine (1985): Jin Zhou Medical College, PR China

ErbB1, ErbB2, and ErbB3 signaling pathways and molecular based targeting of ErbB1 and Erbb2 in cholangiocarcinoma in vitro and in vivo using tyrosine kinase inhibitors and a vector-based siRNA strategy

COX-2 signaling pathways of a spontaneously transformed rat cholangiocarcinoma cell line (BDEsp) originally from a normal bile duct epithelial cell line (BDE1), and molecular based therapy of COX-2 by a vector-based COX-2 siRNA strategy

Lai GH, Zhang Z, Shen XN, Ward DJ, Dewitt JL, Holt SE, Rozich RA, Hixson DC, Sirica AE. ErbB-2/neu transformed rat cholangiocytes recapitulate key cellular and molecular features of human bile duct cancer. Gastroenterology. 2005;129(6):2047-57.

Zhang, Z , Lai, GH, Sirica, AE. Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation. Hepatology. 2004, Apr;39(4):1028-37.

Lai, GH, Zhang, Z, Sirica, AE. Celecoxib acts in a cyclooxygenase-2-independent manner and in synergy with emodin to supress rat cholangiocarcinoma growth in vitro through a mechanism involving enhanced Akt inactivation and increased activation of caspases-9 and -3. Mol Cancer Ther. 2003;2(3):265-71.

Sirica, AE, Lai, GH, Endo K, Zhang Z, Yoon, BI. Cyclooxygenase-2 and ERBB-2 in cholangiocarcinoma: potential therapeutic targets. Semin Liver Disease. 2002; 22(3):303-13.

 Sirica, AE, Lai, GH, and Zhang, Z: Biliary cancer growth factor pathways, cyclo-oxygenase-2 and potential therapeutic strategies. J. Gastroenterology and Hepatology, 2001; 16: 363-372.

Zhang, Z, and Sirica, AE: The cyclooxygenase-2 (COX-2) inhibitor NS- 398 electively suppresses in vitro cell growth and induces apoptosis in C611B rat cholangiocarcinoma cells over-expressing COX-2. 2001; The FASEB J., 15: A1181.

Zhang, Z , Liong E, Tipoe, GL, et al.: Induction of apoptosis by hexamethylene bisacetamide is p53-dependently associated with telomerase activity but not with terminal differentiation in human colon carcinoma cells. International Journal of Oncology. 2000; 16: 886-892.